eptinezumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	May 11, 2022
Call for patient/clinician input closed	July 04, 2022
Clarification: - Patient input submission received from Migraine Canada & Migraine Quebec
Submission received	June 08, 2022
Submission accepted
Review initiated	June 23, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	September 08, 2022
Deadline for sponsors comments	September 19, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	October 14, 2022
Expert committee meeting (initial)	October 26, 2022
Draft recommendation issued to sponsor	November 08, 2022
Draft recommendation posted for stakeholder feedback	November 17, 2022
End of feedback period	December 01, 2022
Final recommendation issued to sponsor and drug plans	December 15, 2022
Final recommendation posted	January 10, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	January 06, 2023
Canada's Drug Agency review report(s) posted	March 15, 2023

Last Updated : March 15, 2023

deferiprone

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	May 10, 2022
Call for patient/clinician input closed	July 04, 2022
Clarification: - Patient input submission received from the Sickle Cell Awareness Group of Ontario and Thalassemia Foundation of Canada
Submission received	June 08, 2022
Submission accepted	June 22, 2022
Review initiated	June 23, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	September 22, 2022
Deadline for sponsors comments	October 03, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	November 11, 2022
Expert committee meeting (initial)	November 23, 2022
Draft recommendation issued to sponsor	December 06, 2022
Draft recommendation posted for stakeholder feedback	December 15, 2022
End of feedback period	January 06, 2023
Final recommendation issued to sponsor and drug plans	January 19, 2023
Final recommendation posted	February 07, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	February 03, 2023
Canada's Drug Agency review report(s) posted	April 27, 2023

Last Updated : April 27, 2023

ravulizumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	May 10, 2022
Call for patient/clinician input closed	July 04, 2022
Clarification: - Patient input submission received from aHUS Canada
Submission received	June 08, 2022
Submission accepted	June 22, 2022
Review initiated	June 23, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	September 08, 2022
Deadline for sponsors comments	September 19, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	October 14, 2022
Expert committee meeting (initial)	October 26, 2022
Draft recommendation issued to sponsor	November 08, 2022
Draft recommendation posted for stakeholder feedback	November 17, 2022
End of feedback period	December 01, 2022
Clarification: - Reconsideration: minor revisions requested by drug programs
Final recommendation posted	March 15, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	March 13, 2023
Canada's Drug Agency review report(s) posted	June 07, 2023

Last Updated : June 8, 2023

dexamethasone intravitreal implant

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	09-May-22
Call for patient/clinician input closed	04-Jul-22
Clarification: - Patient input submission received from CNIB, Diabetes Canada, Fighting Blindness Canada, The Canadian Council of the Blind and Vision Loss Rehabilitation Canada
Submission received	08-Jun-22
Submission accepted	22-Jun-22
Review initiated	23-Jun-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	12-Sep-22
Deadline for sponsors comments	21-Sep-22
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	14-Oct-22
Expert committee meeting (initial)	26-Oct-22
Draft recommendation issued to sponsor	09-Nov-22
Draft recommendation posted for stakeholder feedback	17-Nov-22
End of feedback period	01-Dec-22
Final recommendation issued to sponsor and drug plans	13-Dec-22
Final recommendation posted	06-Jan-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	04-Jan-23
Canada's Drug Agency review report(s) posted	10-Mar-23

Last Updated : July 23, 2024

caplacizumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	May 09, 2022
Call for patient/clinician input closed	July 04, 2022
Clarification: - Patient input submission received from Answering T.T.P. (Thrombotic Thrombocytopenic Purpura) Foundation
Submission received	June 07, 2022
Submission accepted	June 21, 2022
Review initiated	June 22, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	September 07, 2022
Deadline for sponsors comments	September 16, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	October 14, 2022
Expert committee meeting (initial)	October 26, 2022
Draft recommendation issued to sponsor	November 07, 2022
Draft recommendation posted for stakeholder feedback	November 17, 2022
End of feedback period	December 01, 2022
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	March 22, 2023
Final recommendation issued to sponsor and drug plans	April 05, 2023
Final recommendation posted	April 24, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	April 20, 2023
Canada's Drug Agency review report(s) posted	July 13, 2023

Last Updated : July 13, 2023

finerenone

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	April 22, 2022
Call for patient/clinician input closed	June 17, 2022
Clarification: - Patient input submission received from The Kidney Foundation of Canada, Diabetes Canada
Submission received	May 20, 2022
Submission accepted	June 06, 2022
Review initiated	June 07, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	August 30, 2022
Deadline for sponsors comments	September 09, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	October 14, 2022
Expert committee meeting (initial)	October 26, 2022
Draft recommendation issued to sponsor	November 07, 2022
Draft recommendation posted for stakeholder feedback	November 17, 2022
End of feedback period	December 01, 2022
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	February 22, 2023
Final recommendation issued to sponsor and drug plans	March 08, 2023
Final recommendation posted	March 27, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	March 23, 2023
Canada's Drug Agency review report(s) posted	May 18, 2023

Last Updated : May 23, 2023

pembrolizumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	April 22, 2022
Call for patient/clinician input closed	June 17, 2022
Clarification: - Patient input submission received from HPV Global Action
Submission received	May 20, 2022
Submission accepted	June 06, 2022
Review initiated	June 07, 2022
Draft CADTH review report(s) provided to sponsor for comment	August 22, 2022
Deadline for sponsors comments	August 31, 2022
CADTH review report(s) and responses to comments provided to sponsor	September 29, 2022
Expert committee meeting (initial)	October 12, 2022
Draft recommendation issued to sponsor	October 26, 2022
Draft recommendation posted for stakeholder feedback	November 03, 2022
End of feedback period	November 17, 2022
Final recommendation issued to sponsor and drug plans	December 01, 2022
Final recommendation posted	December 19, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	December 15, 2022
CADTH review report(s) posted	March 10, 2023

Last Updated : January 29, 2025

mepolizumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	April 12, 2022
Call for patient/clinician input closed	June 06, 2022
Clarification: - Patient input submission received from Asthma Canada and British Columbia Lung Association & Lung Groups
Submission received	May 11, 2022
Submission accepted	May 26, 2022
Review initiated	May 27, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	August 15, 2022
Deadline for sponsors comments	August 24, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	September 16, 2022
Expert committee meeting (initial)	September 28, 2022
Draft recommendation issued to sponsor	October 11, 2022
Draft recommendation posted for stakeholder feedback	October 20, 2022
End of feedback period	November 03, 2022
Final recommendation issued to sponsor and drug plans	November 16, 2022
Final recommendation posted	December 02, 2022
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	November 30, 2022
Canada's Drug Agency review report(s) posted	February 28, 2023

Last Updated : February 27, 2023

lumasiran

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	April 11, 2022
Call for patient/clinician input closed	June 06, 2022
Clarification: - Patient input submission received from The Oxalosis & Hyperoxaluria Foundation (OHF) and the Canadian Organization for Rare Disorders (CORD)
Submission received	May 10, 2022
Submission accepted	May 26, 2022
Clarification: - Submission was not accepted for review on 25 May 2022
Review initiated	May 27, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	August 11, 2022
Deadline for sponsors comments	August 22, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	September 16, 2022
Expert committee meeting (initial)	September 28, 2022
Draft recommendation issued to sponsor	October 11, 2022
Draft recommendation posted for stakeholder feedback	October 20, 2022
End of feedback period	November 03, 2022
Clarification: - Reconsideration: minor revisions requested by sponsor - Reconsideration accepted
Final recommendation issued to sponsor and drug plans	February 08, 2023
Final recommendation posted	February 27, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	February 23, 2023
Canada's Drug Agency review report(s) posted	April 24, 2023

Last Updated : April 25, 2023

guselkumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	April 01, 2022
Call for patient/clinician input closed	May 30, 2022
Clarification: - Patient input submission received from Arthritis Consumer Experts, Canadian Arthritis Patient Alliance, Arthritis Society & CreakyJoints, Canadian Association of Psoriasis Patients (CAPP) and Canadian Psoriasis Network (CPN)
Submission received	May 02, 2022
Submission accepted	May 16, 2022
Review initiated	May 17, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	August 09, 2022
Deadline for sponsors comments	August 18, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	September 16, 2022
Expert committee meeting (initial)	September 28, 2022
Draft recommendation issued to sponsor	October 13, 2022
Draft recommendation posted for stakeholder feedback	October 20, 2022
End of feedback period	November 03, 2022
Final recommendation issued to sponsor and drug plans	November 17, 2022
Final recommendation posted	December 05, 2022
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	December 01, 2022
Canada's Drug Agency review report(s) posted	February 27, 2023

Last Updated : February 27, 2023